-
公开(公告)号：US12084426B2
公开(公告)日：2024-09-10
申请号：US17274227
申请日：2019-09-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Junqing Guo , Carolyn Diane Dzierba , Amy C. Hart , John E. Macor , William J. Pitts
IPC: C07D401/04 , C07D401/14 , C07D403/04 , C07D413/04 , C07D413/14
CPC classification number: C07D401/04 , C07D401/14 , C07D403/04 , C07D413/04 , C07D413/14
Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
-
公开(公告)号：US20220315580A1
公开(公告)日：2022-10-06
申请号：US17116016
申请日：2020-12-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Junqing Guo , Amy C. Hart , John E. Macor , Michael E. Mertzman , William J. Pitts , Steven H. Spergel , Scott Hunter Watterson , Murugaiah Andappan Murugaiah Subbaiah , Jie Chen , Carolyn Diane Dzierba , Guanglin Luo , Jianliang Shi , Sing-Yuen Sit
IPC: C07D471/04
Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
-
公开(公告)号：US20200347071A1
公开(公告)日：2020-11-05
申请号：US16963886
申请日：2019-01-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Scott Hunter Watterson , Murugaiah Andappan Murugaiah Subbaiah , Carolyn Diane Dzierba , Hua Gong , Jason M. Guernon , Junqing Guo , Amy C. Hart , Guanglin Luo , John E. Macor , William J. Pitts , Jianliang Shi , Brian Lee Venables , Carolyn A. Weigelt , Yong-Jin Wu , Zhizhen Barbara Zheng , Sing-Yuen Sit , Jie Chen
IPC: C07D487/04
Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
-
公开(公告)号：US10023562B2
公开(公告)日：2018-07-17
申请号：US15480682
申请日：2017-04-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC: C07D401/12 , C07D407/14 , C07D405/12 , C07D213/74 , C07D405/14 , C07D401/14 , C07D417/14
Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
-
公开(公告)号：US20170210730A1
公开(公告)日：2017-07-27
申请号：US15480682
申请日：2017-04-06
Applicant: Bristol-Myers Squibb Company
Inventor： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC: C07D407/14 , C07D213/74 , C07D417/14 , C07D405/14 , C07D401/14 , C07D405/12 , C07D401/12
CPC classification number: C07D407/14 , C07D213/74 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/14
Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
-
Patent Agency Ranking
6.发明授权Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators 有权用作激酶调节剂的双环杂环取代的吡啶基化合物公开(公告)号：US09546153B2
公开(公告)日：2017-01-17
申请号：US14441698
申请日：2013-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC: C07D401/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07D513/04 , C07D417/14 , C07D471/04
CPC classification number: C07D401/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 2是双环杂环，并且R 1，R 3，R 4，R 5和R 6如本文所定义，其可用作激酶调节剂，包括IRAK -4调制。
-
7.发明授权Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases 有权咪唑并哒嗪JAK3抑制剂及其用于治疗炎症和自身免疫性疾病的用途公开(公告)号：US09428511B2
公开(公告)日：2016-08-30
申请号：US14426625
申请日：2013-09-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Bingwei Vera Yang , Gregory D. Brown , Arun Kumar Gupta , William J. Pitts
IPC: C07D487/04 , C07B59/00
CPC classification number: C07D487/04 , C07B59/002 , C07B2200/05
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式I化合物抑制JAK3的酪氨酸激酶活性，从而使其可用于治疗炎症和自身免疫性疾病。
-
8.发明授权公开(公告)号：US08987311B2
公开(公告)日：2015-03-24
申请号：US14371281
申请日：2013-01-11
Applicant: Bristol-Myers Squibb Company
Inventor： Dharmpal S. Dodd , Christopher P. Mussari , Rajeev S. Bhide , Satheesh Kesavan Nair , Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , William J. Pitts , John Hynes
IPC: C07D401/04 , A61K31/44 , C07D471/10 , C07D417/14
CPC classification number: C07D471/10 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula: (I) wherein: A is an optionally substituted triazole, or a stereoisomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式的化合物：（I）其中：A是任选取代的三唑或其立体异构体或其药学上可接受的盐，可用作激酶调节剂，包括IRAK-4调节。
-
公开(公告)号：US12157733B2
公开(公告)日：2024-12-03
申请号：US17116016
申请日：2020-12-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Junqing Guo , Amy C. Hart , John E. Macor , Michael E. Mertzman , William J. Pitts , Steven H. Spergel , Scott Hunter Watterson , Murugaiah Andappan Murugaiah Subbaiah , Jie Chen , Carolyn Diane Dzierba , Guanglin Luo , Jianliang Shi , Sing-Yuen Sit
IPC: C07D471/04
Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
-
公开(公告)号：US11618753B2
公开(公告)日：2023-04-04
申请号：US16963886
申请日：2019-01-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Scott Hunter Watterson , Murugaiah Andappan Murugaiah Subbaiah , Carolyn Diane Dzierba , Hua Gong , Jason M. Guernon , Junqing Guo , Amy C. Hart , Guanglin Luo , John E. Macor , William J. Pitts , Jianliang Shi , Brian Lee Venables , Carolyn A. Weigelt , Yong-Jin Wu , Zhizhen Barbara Zheng , Sing-Yuen Sit , Jie Chen
IPC: A61K31/53 , C07D253/08 , C07D487/04
Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.04 seconds)
